Enterome

Enterome is a clinical-stage biopharmaceutical company focused on developing breakthrough immunomodulatory drugs for the treatment of cancer, known as OncoMimics™ peptides. Its drug discovery approach is based on its ability to decode the interaction between the gut microbiome and the immune system, using a Mimicry platform with biocomputational tools and bioassays applied to a proprietary database of 20+ million full-length gut microbiome proteins. The company is advancing a proprietary OncoMimics™ pipeline including EO2463 in indolent non-Hodgkin lymphomas, EO2401 in glioblastoma and adrenal tumors, and EO4010 for third-line colorectal cancer. It is headquartered in Paris, France, and was co-founded by Pierre Belichard, who has led the company since its inception in 2012.

Enterome is a clinical-stage biopharmaceutical company focused on developing breakthrough immunomodulatory drugs for the treatment of cancer, known as OncoMimics™ peptides. Its pioneering approach to drug discovery is based on its unique ability to decode the interaction between the gut microbiome and the immune system. The company's Mimicry platform uses biocomputational tools and bioassays to identify novel therapeutics from its proprietary database of 20+ million full-length gut microbiome proteins. Enterome was co-founded by Pierre Belichard, who has led the company since its inception in 2012. The company is headquartered in Paris, France.

Clinical-stage biopharmaceutical company developing off-the-shelf, transformational cancer treatments targeting a wide range of tumor types.

• OncoMimics™ peptides

  Breakthrough immunomodulatory drugs for the treatment of cancer.

• EO2463

  OncoMimics™ drug candidate in indolent non-Hodgkin lymphomas.

• EO2401

  OncoMimics™ drug candidate in glioblastoma and adrenal tumors.

• EO4010

  OncoMimics™ drug candidate for third-line colorectal cancer.

1. 1Enteromeenterome.com
2. 2Enteromeenterome.com